Furthermore, the authors used CRISPR/Cas9 system to knocked-out p53 and pRB in HPV+ LSCC cells and found both p53 and pRB can affect the sensitivity to radiotherapy and the specific molecular mechanism of action and provide a more sufficient theoretical and experimental basis for the selection of patients with laryngeal cancer radiotherapy advantages. This evidence concerns the gene TP53 and laryngeal carcinoma.